Managers / Q2 2024 · view latest →
Propel Bio Management, LLC
CIK 0001969764 · 11620 WILSHIRE BLVD.,, SUITE 350, LOS ANGELES, CA, 90025 · 908-507-9629
Summary
Propel Bio Management, LLC reported $154M in U.S.-listed holdings across 25 positions for Q2 2024.
Its largest position, APLT, represents 19.9% of the portfolio.
Compared with Q1 2024, the fund opened 4 new positions and exited 8.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 77.5% · $119M
- Ltd Part · 16.8% · $26M
- Other · 4.8% · $7M
- Closed-End Fund · 1.0% · $2M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| PAGPPLAINS GP HOLDINGS LP-CL | NEW | +1.37M | 1.37M | +$26M | $26M |
| ABEOABEONA THERAPEUTICS INC | NEW | +1.25M | 1.25M | +$5M | $5M |
| VERRICA PHARMACEUTICALS I | NEW | +424.9K | 424.9K | +$3M | $3M |
| MAAT PHARMA SACA | NEW | +1.4K | 1.4K | +$9,752 | $9,752 |
| HIGHSIMPLIFY ENHANCED INCOME | SOLD OUT | −1.49M | 0 | −$28M | $0 |
| DAY ONE BIOPHARMACEUTICALS I | SOLD OUT | −270.7K | 0 | −$4M | $0 |
| MBBISHARES MBS ETF | SOLD OUT | −22.4K | 0 | −$2M | $0 |
| MIRMMIRUM PHARMACEUTICALS INC | SOLD OUT | −70.0K | 0 | −$2M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2024
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $159M | 38 | May 14, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $117M | 20 | Feb 11, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $100M | 16 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $82M | 16 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $86M | 18 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $101M | 21 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $172M | 21 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $154M | 25 | Aug 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $172M | 29 | May 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $121M | 34 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Simplify Asset Management Inc.028-20937
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.